Skip to content

Time Course of Resolution of Diabetic Macular Edema by Sustained Suppression of VEGF-A with the Port Delivery Platform with Ranibizumab.

Oct 2026 · American journal of ophthalmology-glaucoma · 0 citations · 17 references
Medicine

TL;DR

Sustained suppression of VEGF-A is sufficient to effectively treat DME in the vast majority of patients, but edema resolution may be slow in some patients giving the false impression of poor response to anti-VEGF-A treatment.

Abstract

Purpose

To determine the incidence of poor responsiveness to VEGF-A suppression in eyes with diabetic macular edema (DME) by evaluating the effect of continuous delivery of ranibizumab via the Port Delivery Platform with ranibizumab (PDS) in individual patients enrolled in the Pagoda clinical trial.

Design

Retrospective analysis of prospective clinical trial data SUBJECTS: DME patients enrolled in Pagoda (NCT04108156).

Methods

Change in central subfield thickness (CST) and best-corrected visual acuity (BCVA) over time was evaluated for the adjusted intent-to-treat (aITT) population in the Pagoda trial. Optical coherence tomography (OCT) images obtained at each visit were analyzed for 56 PDS subjects from 8 sites to determine the time course of changes in intraretinal and subretinal fluid. MAIN OUTCOME MEASURES CST, BCVA, and time to resolution of edema.

Results

In the aITT population the mean duration of follow up was 107.7 weeks in the PDS arm (n=272) and 100.7 weeks the IVT-PDS arm (n=238). The percentage of eyes with CST improvement into the normal range (≤325 µm) by the last visit was 87.9% in the PDS group and 85.3% in the IVT-PDS arm with mean time to normalization of 21.3 weeks and 20.6 weeks, respectively. All eyes in both arms showed reduction in CST over time although some exhibited periods of CST fluctuation and a few in each arm showed initial improvement followed by worsening at last follow up. In the eyes of 56 PDS patients that had detailed analysis of OCTs, normalization of CST occurred in 93% at a median of 17 weeks and elimination of intraretinal fluid in the central 1mm occurred in 84% at a median of 68 weeks. Only 3 of 56 eyes had poorly controlled DME at last follow up.

Conclusions

Sustained suppression of VEGF-A is sufficient to effectively treat DME in the vast majority of patients, but edema resolution may be slow in some patients giving the false impression of poor response to anti-VEGF-A treatment. In DME, the term unresponsive to anti-VEGF-A treatment should be replaced by slowly responsive.

View source

Similar papers

Open access Sep 2026

Response to anti-VEGF injections for diabetic macular edema among patients on chronic exogenous insulin therapy.

It is suggested that the chronic use of exogenous insulin may not influence the functional or anatomic response to anti-VEGF injections in diabetic patients on chronic exogenous insulin therapy.

Jonathan D. Groothoff, Annie G. Elander, Sean K. Wang et al. · 0 citations
Open access Oct 2026

Comparative study of the efficacy of intravitreal ranibizumab versus its combination with intravitreal dexamethasone in the treatment of diabetic macular edema

Diabetic macular edema imposes a substantial cause of central vision loss worldwide. Anti- vascular endothelial growth factor therapy, such as ranibizumab, has become the standard of care for diabetic macular edema. In this study, we investigated the effect of using combined therapy of ranibizumab and dexamethasone...

Mohamed A. M. Aly, Mahmoud O. Khaled, K. Abueleinen et al. · 0 citations
Open access Oct 2026

Outcomes of Intravitreal Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Kazakhstan

Background: Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss among older adults. Although randomised controlled trials have demonstrated the robust efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, real-world outcomes often differ mar...

M. Suleimenov, B. Kadyrgaliyev, E. Kanafyanova et al. · 0 citations
Open access Nov 2026

Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response

Purpose To evaluate 12-month outcomes of switching to faricimab in eyes with neovascular age-related macular degeneration (nAMD) in Chinese patients showing inadequate response to aflibercept, and explore correlations between dynamic changes in subretinal hyperreflective material (SHRM) height, treatment interval and v...

Jing Wang, Feng-Jiao Li, Ya-Lin Wang et al. · 0 citations
Open access Sep 2026

Improvement in visual outcomes in diabetic macular edema through the reduction of macular thickness fluctuations using the 0, 19 mg fluocinolone acetonide implant

This study aimed to assess the effectiveness of 0.19-mg fluocinolone acetonide intravitreal (FAc) implant to control retinal thickness fluctuations (RTF) in diabetic macular edema (DME) and its effect on best-corrected visual acuity (BCVA). The RIVER study was a multicenter, retrospective, non-interventional study anal...

S. Penas, B. Pessoa, Carla Teixeira et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.